Biocon Limited Opens First U.S. Manufacturing Facility in Cranbury, New Jersey

Biocon Limited, a global biopharmaceutical company based in Bengaluru, India, has opened its first manufacturing facility in the United States. The new facility, located in Cranbury, New Jersey, marks a significant milestone for the company as it expands its operations internationally. The plant is operated by Biocon’s wholly owned subsidiary and aims to strengthen the company’s presence in the U.S. market.

The inauguration of the Cranbury facility highlights Biocon’s commitment to scaling up its manufacturing capabilities to meet growing demand. The move aligns with the company’s broader strategy of enhancing its global footprint and providing high-quality biopharmaceutical products to international markets. Further details about the size, capacity, or specific focus of the new facility were not disclosed at this time.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

Date: September 10, 2025

Related posts:

Generic Drug Approval Faces Hurdles: Stringent FDA Regulations and Bioequivalence Studies Challenge ANDA Submissions Experts: Patient Journey Understanding, Complex Value Chain Management, and Targeted Patient Matching Drive Successful Adoption of New Medical Treatments Global Regulations Mandate Secure Packaging and Accurate Labeling for Medical Devices to Ensure Patient Safety FDA Approves Pegcetacoplan for Treating Rare Kidney Diseases C3G and IC-MPGN

Author

Mark Chiang